Orthofix Q2 2023 revenue $187M (+7% pro forma), raises FY adjusted EBITDA guidance

Orthofix Medical Inc.

2023-Q2 EPS reported -$2.77 revenue$362,220,000

Net sales $187.0M, up 58% reported / 7% pro forma constant currency YoY.
GAAP EPS $(1.07); adjusted EPS $0.02; adjusted EBITDA $9.9M (5.3% margin).
Bone Growth Therapies grew 10.3% YoY; U.S. spine implants +7% pro forma.
FY23 net sales guidance raised to $752-758M; adjusted EBITDA to $42-46M.
Full commercial launch of WaveForm A interbody and TrueLok Phantom/Tornado hinges.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Orthofix Medical Inc. reported the quarter ended June 30, 2023 results: revenue $187.0 million, EPS $(1.07). Guidance raised.

Period: the quarter ended June 30, 2023
Revenue: $187.0 million
EPS: $(1.07)
Guidance: raised
Result: reported results

Exact text from the filing

Legal judgments/sett --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Orthofix Reports Second Quarter 2023 Results and Raises Revenue and Adjusted EBITDA Guidance • Net sales of $187.0 million, an increase of 58% on a reported basis and 7% on a pro forma constant currency basis over prior year • Bone Growth Therapies growth of 10%, marking two consecutive quarters with

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

Orthofix Medical Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039871

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.